Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Nat Prod ; 86(4): 797-803, 2023 04 28.
Article in English | MEDLINE | ID: mdl-36857574

ABSTRACT

Leishmaniasis is a neglected disease caused by flagellated parasites of the Leishmania genus affecting more than 10 million people worldwide. Current treatments for leishmaniasis involve the administration of poorly tolerated drugs with toxic side effects in patients. There is an imperative necessity for novel compounds to treat this disease. One of the most used strategies in the search for different antiparasitic compounds is the screening of purified plant molecules. The diterpenes 12-hydroxy-11,14-diketo-6,8,12-abietatrien-19,20-olide (HABTO) and 5-epi-icetexone (ICTX) isolated from Salvia cuspidata were shown to be effective against Leishmania amazonensis in vitro and in vivo. They displayed an antiproliferative effect against L. amazonensis promastigotes. They also induce an increase in ROS levels and affect the mitochondrial activity of parasites. HABTO and ICTX in an in vivo model of cutaneous leishmaniasis decrease footpad swelling, parasite load, and splenic index. Moreover, they induce significant reduction in the O.D. of total anti-Leishmania IgG and IgG1 subtype antibody responses against L. amazonensis compared to the PBS group but maintain high levels of IgG2a. This suggests that in HABTO- or ICTX-treated mice, there is a slowdown in the progression of the disease. These terpenes could be considered as possible novel antileishmanial agents against L. amazonensis and thus treat cutaneous leishmaniasis.


Subject(s)
Antiprotozoal Agents , Leishmania mexicana , Leishmania , Leishmaniasis, Cutaneous , Salvia , Animals , Mice , Antiparasitic Agents/pharmacology , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use , Leishmaniasis, Cutaneous/drug therapy , Mice, Inbred BALB C , Terpenes/pharmacology
2.
J Tradit Complement Med ; 12(3): 281-286, 2022 May.
Article in English | MEDLINE | ID: mdl-35493311

ABSTRACT

Background and aim: Prosopis strombulifera (Lam.) Benth is a rhizomatous shrub native from different zones of Argentine Republic. P. strombulifera aqueous extract (PsAE) has different effects and several biological activities have been reported. The goal of this study was to analyze the activity of PsAE on a murine model of cutaneous leishmaniasis caused by Leishmania amazonensis. Experimental procedure: PsAE was orally administered at 150 mg/animal/day on BALB/c mice infected in the right footpad (RFP) with 1 × 105 promastigotes of L. amazonensis. As a chemotherapeutic control of treatment, animals receive a commercial form of meglumine antimoniate (MA) (Glucantime®, Aventis, Paris, France). Results and conclusion: We observe that the size of RFP lesions of infected mice without treatment showed a grade of inflammation, ulceration and necrosis at the site of infection much greater than that observed with PsAE or MA treatment. Moreover, PsAE was capable of decreasing parasite burden and splenic index. Furthermore, PsAE treated mice showed a significant decrease in O.D. of total anti-Leishmania IgG antibody responses against L. amazonensis. This decrease was similar to those observed when the reference drug, MA, was used. This would indicate that PsAE treatment inhibits or delays disease progression in mice. In conclusion, our findings suggest that PsAE could be a potential candidate to be used, as a new therapeutic strategy, to treat cutaneous leishmaniasis caused by L. amazonensis.

3.
Rev. argent. microbiol ; 53(3): 21-30, Sept. 2021. graf
Article in English | LILACS | ID: biblio-1376412

ABSTRACT

ABSTRACT Leishmaniasis is a group of parasitic zoonotic diseases caused by intracellular protozoans belonging to the genusLeishmania. Little is known about the effects that this parasitosis may have on the reproductive parameters and pregnancy of infected humans and pets. This study aimed to evaluate the influence of chronic cutaneous leishmaniasis caused byLeishmania (Leishmania) amazonensison reproductive and fetal parameters using a female murine model. A control group of female BALB/c mice and a group infected withL. (L.) amazonensiswere mated with healthy males. Clinical parameters were monitored during the pre-mating and gestational periods. Female mice were euthanized on day 19 of gestation, when the fetuses were weighed and their length measured and embryonic resorptions and fetal death were recorded. We observed five fetal deaths and three embryonic resorptions in the infected group. Furthermore, there was a decrease in fertility in the infected group (26.32%). The weight of the offspring from infected mothers was lower than that in the control group (1.019±0.035g and 1.163±0.032g,p<0.01). Fetal length was reduced in the infected group (3.71±0.05cm in the control group and 3.40±0.06cm in the infected groupp<0.001). This study shows that cutaneous leishmaniasis caused byL. (L.) amazonensisimpairs reproductive and fetal parameters in mice.


RESUMEN La leishmaniasis comprende un grupo de enfermedades zoonóticas parasitarias causadas por protozoos intracelulares pertenecientes al géneroLeishmania. Poco se conoce sobre los efectos que esta parasitosis puede tener sobre los parámetros reproductivos y la gestación en humanos y en otras especies infectadas. El objetivo de este estudio fue determinar la influencia de la leishmaniasis cutánea crónica, causada porLeishmania (Leishmania) amazonensis, en parámetros reproductivos y fetales. Se apareó un grupo control y un grupo infectado de ratones hembra BALB/c (previamente inoculado conL. (L.) amazonensis) con machos sanos. Se analizaron parámetros clínicos durante los períodos pregestacional y gestacional. Las hembras fueron eutanasiadas en el día 19 de gestación, momento en el cual se pesaron y midieron los fetos y se registraron las reabsorciones embrionarias y las muertes fetales. Se observaron 5 muertes fetales y 3 reabsorciones embrionarias en el grupo infectado. Además, hubo una disminución en la fertilidad de este último grupo (26,32%). Por otra parte, el peso de la descendencia de madres infectadas fue menor que el del grupo control (1,019±0,035g y 1,163±0,032g, respectivamente,p<0,01). Por último, la longitud fetal se redujo en el grupo infectado (3,71±0,05cm en el grupo control y 3,40±0,06cm en el grupo infectado,p<0,001). Este estudio muestra que la leishmaniasis cutánea causada porL. (L.) amazonensisafecta los parámetros reproductivos y fetales en ratones.


Subject(s)
Animals , Female , Male , Mice , Pregnancy , Leishmaniasis, Cutaneous , Leishmania , Fetus , Mice, Inbred BALB C
4.
Front Cell Infect Microbiol ; 11: 666746, 2021.
Article in English | MEDLINE | ID: mdl-34150675

ABSTRACT

Antimonials continue to be considered the first-line treatment for leishmaniases, but its use entails a wide range of side effects and serious reactions. The search of new drugs requires the development of methods more sensitive and faster than the conventional ones. We developed and validated a fluorescence assay based in the expression of tdTomato protein by Leishmania, and we applied this method to evaluate the activity in vitro of flavonoids and reference drugs. The pIR1SAT/tdTomato was constructed and integrated into the genome of Leishmania (Leishmania) amazonensis. Parasites were selected with nourseothricin (NTC). The relation of L. amaz/tc3 fluorescence and the number of parasites was determined; then the growth in vitro and infectivity in BALB/c mice was characterized. To validate the fluorescence assay, the efficacy of miltefosine and meglumine antimoniate was compared with the conventional methods. After that, the method was used to assess in vitro the activity of flavonoids; and the mechanism of action of the most active compound was evaluated by transmission electron microscopy and ELISA. A linear correlation was observed between the emission of fluorescence of L. amaz/tc3 and the number of parasites (r2 = 0.98), and the fluorescence was stable in the absence of NTC. No differences were observed in terms of infectivity between L. amaz/tc3 and wild strain. The efficacy of miltefosine and meglumine antimoniate determined by the fluorescence assay and the microscopic test showed no differences, however, in vivo the fluorescence assay was more sensitive than limiting dilution assay. Screening assay revealed that the flavonoid galangin (GAL) was the most active compound with IC50 values of 53.09 µM and 20.59 µM in promastigotes and intracellular amastigotes, respectively. Furthermore, GAL induced mitochondrial swelling, lipid inclusion bodies and vacuolization in promastigotes; and up-modulated the production of IL-12 p70 in infected macrophages. The fluorescence assay is a useful tool to assess the anti-leishmanial activity of new compounds. However, the assay has some limitations in the macrophage-amastigote model that might be related with an interfere of flavanol aglycones with the fluorescence readout of tdTomato. Finally, GAL is a promising candidate for the development of new treatment against the leishmaniasis.


Subject(s)
Antiprotozoal Agents , Leishmania , Pharmaceutical Preparations , Animals , Antiprotozoal Agents/therapeutic use , Flavonoids , Luminescent Proteins , Mice , Mice, Inbred BALB C , Red Fluorescent Protein
5.
Acta Trop ; 221: 105988, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34058160

ABSTRACT

Leishmaniasis is a Neglected Tropical Diseases caused by protozoan parasites of the genus Leishmania. It is a major health problem in many tropical and subtropical regions of the world and can produce three different clinical manifestations, among which cutaneous leishmaniasis has a higher incidence in the world than the other clinical forms. There are no recognized and reliable means of chemoprophylaxis or vaccination against infections with different forms of leishmaniasis. In addition, chemotherapy, unfortunately, remains, in many respects, unsatisfactory. Therefore, there is a continuing and urgent need for new therapies against leishmaniasis that are safe and effective in inducing a long-term cure. This review summarizes the latest advances in currently available treatments and improvements in the development of drug administration. In addition, an analysis of the in vivo assays was performed and the challenges facing promising strategies to treat CL are discussed. The treatment of leishmaniasis will most likely evolve into an approach that uses multiple therapies simultaneously to reduce the possibility of developing drug resistance. There is a continuous effort to discover new drugs to improve the treatment of leishmaniasis, but this is mainly at the level of individual researchers. Undoubtedly, more funding is needed in this area, as well as greater participation of the pharmaceutical industry to focus efforts on the development of chemotherapeutic agents and vaccines for this and other neglected tropical diseases.


Subject(s)
Leishmania , Leishmaniasis, Cutaneous , Vaccines , Humans , Leishmaniasis , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/prevention & control , Neglected Diseases , Pharmaceutical Preparations
6.
Rev Argent Microbiol ; 53(3): 194-201, 2021.
Article in English | MEDLINE | ID: mdl-33375987

ABSTRACT

Leishmaniasis is a group of parasitic zoonotic diseases caused by intracellular protozoans belonging to the genus Leishmania. Little is known about the effects that this parasitosis may have on the reproductive parameters and pregnancy of infected humans and pets. This study aimed to evaluate the influence of chronic cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis on reproductive and fetal parameters using a female murine model. A control group of female BALB/c mice and a group infected with L. (L.) amazonensis were mated with healthy males. Clinical parameters were monitored during the pre-mating and gestational periods. Female mice were euthanized on day 19 of gestation, when the fetuses were weighed and their length measured and embryonic resorptions and fetal death were recorded. We observed five fetal deaths and three embryonic resorptions in the infected group. Furthermore, there was a decrease in fertility in the infected group (26.32%). The weight of the offspring from infected mothers was lower than that in the control group (1.019±0.035g and 1.163±0.032g, p<0.01). Fetal length was reduced in the infected group (3.71±0.05cm in the control group and 3.40±0.06cm in the infected group p<0.001). This study shows that cutaneous leishmaniasis caused by L. (L.) amazonensis impairs reproductive and fetal parameters in mice.


Subject(s)
Leishmania , Leishmaniasis, Cutaneous , Animals , Female , Fetus , Male , Mice , Mice, Inbred BALB C , Pregnancy
7.
Mem Inst Oswaldo Cruz ; 115: e200067, 2020.
Article in English | MEDLINE | ID: mdl-32667458

ABSTRACT

BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them. OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)]. METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured. FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection. MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.


Subject(s)
Leishmania , Leishmaniasis Vaccines , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/prevention & control , Protozoan Vaccines/immunology , Toll-Like Receptor 3/immunology , Animals , Antigens, Protozoan/immunology , Humans , Mice , Mice, Inbred BALB C
8.
Int. j. odontostomatol. (Print) ; 14(3): 342-347, 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1114904

ABSTRACT

La Leishmaniasis es un grupo de enfermedades transmitidas por vectores y causada por la Leishmania, un parásito intracelular, que se presenta de preferencia en regiones tropicales y subtropicales. Se manifiesta mediante un amplio rango de formas clínicas como la cutánea, mucocutánea, y visceral, dependiendo de la especie y respuesta inmunológica del paciente. Se presenta el caso de un hombre de 35 años que acudió derivado a Unidad de Estomatología del Hospital Señor del Milagro, Salta, Argentina, presentando en la cavidad oral lesión, granulomatosa, ulcerada, dolorosa a la palpación, única, en paladar blando, de tres meses de evolución. Se realizaron estudios serológicos, parasitológicos y PCR. Los ELISAs lisados, PCRs y cultivos de materiales de lesiones fueron positivos, confirmando diagnóstico de leishmaniasis mucocutánea. El paciente fue derivado al Servicio de Dermatología donde recibió tratamiento con Antimoniato de Meglumina, con repuesta clínica favorable. El conocimiento de las manifestaciones orales puede llevar al diagnóstico clínico de leishmaniasis mucocutánea por parte del odontólogo, pudiendo entregar un tratamiento oportuno y a la vez ayudar al paciente, evitando complicaciones de esta enfermedad.


Leishmaniasis is a group of vector-borne diseases caused by Leishmania, an intracellular parasite, which occurs preferentially in tropical and subtropical regions. It manifests itself through a wide range of clinical forms such as cutaneous, mucocutaneous, and visceral, depending on the species and the patient's immune response. We present a case of a 35-year-old man who was referred to the Stomatology Unit of the Señor del Milagro Hospital, Salta, Argentina, presenting in the oral cavity lesion, granulomatous, ulcerated, painful on palpation, unique, soft palate with three months of evolution. Serological, parasitological and PCR studies were performed. Lysed ELISAs, PCRs and cultures of lesion materials were positive, confirming diagnosis of mucocutaneous leishmaniasis. The patient was referred to the Dermatology Service where he received treatment with Meglumine Antimony, with favorable clinical response. The knowledge of the oral manifestations can lead to the clinical diagnosis of mucocutaneous leishmaniasis by the dentist, being able to provide timely treatment and at the same time help the patient, avoiding complications of this disease.


Subject(s)
Humans , Male , Adult , Leishmaniasis, Mucocutaneous/diagnosis , Leishmaniasis, Mucocutaneous/parasitology , Mouth Diseases/diagnosis , Mouth Diseases/parasitology , Paracoccidioidomycosis/diagnosis , Enzyme-Linked Immunosorbent Assay , Polymerase Chain Reaction , Diagnosis, Differential , Histoplasmosis/diagnosis , Leishmania/isolation & purification , Mouth Mucosa/parasitology
9.
Mem. Inst. Oswaldo Cruz ; 115: e200067, 2020. graf
Article in English | LILACS, Sec. Est. Saúde SP | ID: biblio-1135224

ABSTRACT

BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them. OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)]. METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured. FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection. MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.


Subject(s)
Humans , Animals , Mice , Protozoan Vaccines/immunology , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/prevention & control , Toll-Like Receptor 3/immunology , Leishmaniasis Vaccines , Leishmania , Mice, Inbred BALB C , Antigens, Protozoan/immunology
10.
J Microbiol Immunol Infect ; 49(1): 24-32, 2016 Feb.
Article in English | MEDLINE | ID: mdl-24662018

ABSTRACT

BACKGROUND/PURPOSE: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first generation Leishmania vaccine in a murine model. METHODS: Immunization protocols were tested in BALB/c mice with a subcutaneous prime/boost regimen with an interval of 3 weeks. Mice immunized with unadjuvanted TLA and phosphate-buffered saline (PBS) served as control groups. On Day 21 and Day 36 of the protocol, we evaluated the humoral immune response induced by each formulation. Fifteen days after the boost, the immunized mice were challenged with 1 × 10(5) promastigotes of Leishmania (Leishmania) amazonensis in the right footpad (RFP). The progress of the infection was followed for 10 weeks; at the end of this period, histopathological studies were performed in the RFP. RESULTS: Vaccines formulated with Montanide ISA 763 generated an increase in the production of immunoglobulin G (IgG; p < 0.05) compared with the control group. There were no statistically significant differences in IgG1 production between the study groups. However, immunization with TLA-Montanide ISA 763 resulted in an increase in IgG2a compared to the unadjuvanted control (p < 0.001). Also noteworthy was the fact that a significant reduction in swelling and histopathological damage of the RFP was recorded with the Montanide ISA 763 formulation. CONCLUSION: We conclude that the immunization of BALB/c mice with a vaccine formulated with TLA and Montanide ISA 763 generated a protective immune response against L. (L.) amazonensis, characterized by an intense production of IgG2a.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antigens, Protozoan/immunology , Leishmania mexicana/immunology , Leishmaniasis Vaccines/immunology , Leishmaniasis, Cutaneous/prevention & control , Oils/administration & dosage , Animals , Antibodies, Protozoan/blood , Antigens, Protozoan/administration & dosage , Antigens, Protozoan/isolation & purification , Disease Models, Animal , Female , Immunization Schedule , Immunoglobulin G/blood , Injections, Subcutaneous , Leishmaniasis Vaccines/administration & dosage , Leishmaniasis Vaccines/isolation & purification , Leishmaniasis, Cutaneous/immunology , Mice, Inbred BALB C
15.
Rev. colomb. reumatol ; 22(3): 174-179, sep.2015. tab, ilus
Article in Spanish | LILACS | ID: lil-779157

ABSTRACT

El lupus eritematoso sistémico (LES) es una enfermedad autoinmune, de etiología desconocida,que se manifiesta como una enfermedad sistémica pleomórfica, afectando,principalmente, a las mujeres. El mecanismo autoinmune del LES se ha visto asociado aldesarrollo del fenómeno de la célula LE. Este fenómeno consiste en la fagocitosis, por partede los neutrófiflos, de los núcleos liberados por las células opsonizadas por el anticuerpoanti-DNP y el complemento C3b. A partir de diferentes estudios, se ha visto relación multifactorialetiológica en la inducción de enfermedades autoinmunes, en la que se encuentrauna relación infrecuente con el consumo crónico de cocaína. Esto se explica a través deprocesos biológicos en los que se inhibe la fagocitosis de los restos celulares generados pordichas enfermedades. A continuación se presenta el caso de un paciente con antecedentede consumo de derivados de la benzoilecgonina, quien ingresa por manifestaciones constitucionales,pulmonares, renales, cutáneas y musculoesqueléticas, en quien los paraclínicosy la biopsia renal confirman el diagnóstico de LES con nefritis lúpica clase iv. Así mismo, sedestaca la relevancia de sospecha y diagnóstico temprano de dicha enfermedad y la correlacióncon el consumo de cocaína para dar tratamiento oportuno y evitar el progreso y suscomplicaciones...


Subject(s)
Humans , Apoptosis , Autoimmunity , Cocaine , Levamisole , Lupus Erythematosus, Systemic , Vasculitis
16.
Rev. patol. trop ; 44(1): 21-32, 2015. tab, graf
Article in Spanish | LILACS | ID: lil-758562

ABSTRACT

En las normas actuales de tratamiento etiológico de la fase crónica tardía de la enfermedad de Chagasen Argentina, Brasil y la Organización Mundial de la Salud, se recomienda controlar la eficaciaterapéutica con pruebas serológicas y parasitológicas convencionales. Sin embargo las primerassuelen continuar positivas 10 años o más luego del tratamiento, y las segundas son, en general, debaja sensibilidad en esta etapa de la enfermedad. La Reacción en Cadena de la Polimerasa (PCR)al ser más sensible que los exámenes parasitológicos convencionales, podría informar con unacobertura mayor si hubo falla terapéutica. Hemos ofrecido tratamiento con benznidazol (5 mg/kg/día, por 60 días) a 138 pacientes de 16 a 35 años de edad, infectados crónicamente con Trypanosomacruzi. La eficacia terapéutica se controló con PCR periódicas, hemocultivo y serología convencionalen dos grupos de pacientes: uno (GT, 57 pacientes) que aceptó y cumplió el tratamiento y otro(GNT, 37 pacientes) que lo rechazó. Antes de la administración de benznidazol la PCR mostró unasensibilidad diagnóstica de 41 por ciento (57/138 pacientes) y el hemocultivo 7,2 por ciento (10/138). Sesenta mesespostratamiento el grupo GT mostró una positividad de PCR acumulada de 28,1 por ciento (16/57) y el grupoGNT 54,1 por ciento (20/37; p=0.0016). A pesar de que la sensibilidad diagnóstica de PCR es limitada, lanegatividad de pruebas repetidas con método normatizado podría evidenciar disminución de laparasitemia o probable curación en 71,9 por ciento de los pacientes tratados, lo que habría que confirmar conel seguimiento serológico...


Current norms for the etiological treatment of chronic Chagas disease, recommended by WHOor currently in force for Argentina and Brazil, advise the control of therapeutic efficacy usingconventional serological and parasitological tests. However, serology usually remains positive 10 ormore years after treatment and parasitological tests are insensitive in the chronic stage. PolymeraseChain Reaction (PCR) is more sensitive than parasitological tests and could provide earlier evidenceof therapeutic failure. We offered benznidazole treatment (5 mg/kg/day, 60 days) to 138 patients(age=16 to 35 years old), chronically infected with Trypanosoma cruzi. Therapeutic efficacy waschecked with periodic PCR, haemoculture and conventional serology in two groups of patients: One(TG) accepting and complying with treatment and the other (NTG) rejecting it. Before benznidazoleadministration, PCR displayed a diagnostic sensitivity of 41.3 percent (57/138) and haemoculture 7.2 percent(10/138). Sixty months after treatment, TG displayed a cumulated PCR positivity of 28.1 percent (16/57)and NTG 54.1 percent (20/37; p=0.0166). Even though the sensitivity of PCR is limited, repeated negativeresults of a standardized method may reveal lower parasitaemia or probable cure, in 71.9 percent of treatedpatients, to be confirmed with serological follow up...


Subject(s)
Humans , Antiparasitic Agents , Chagas Disease/diagnosis , Trypanosoma cruzi , Enzyme-Linked Immunosorbent Assay , Polymerase Chain Reaction
17.
Acta bioquím. clín. latinoam ; 47(1): 53-59, mar. 2013. graf
Article in Spanish | LILACS | ID: lil-727423

ABSTRACT

La ceruloplasmina (CP) es una proteína que participa en el metabolismo del hierro y transporta el 95% del cobre plasmático. Se considera un inhibidor fisiológico de la mieloperoxidasa (MPO), enzima leucocitaria que forma parte del sistema inmune innato. Ambas se postulan como biomarcadores de la enfermedad cardiovascular. El objetivo del presente trabajo fue determinar la actividad de CP y la concentración de MPO en pacientes con enfermedad coronaria crónica (ECC) y analizar su asociación con otros parámetros de inflamación. Se estudiaron 22 pacientes con ECC y 22 controles sanos. La actividad de CP fue determinada por el método de Ozcan Erel y las concentraciones de MPO, proteína C- reactiva ultrasensible (PCR-us) e Interleuquina 6 (IL-6) por métodos estandarizados. La concentración de MPO y la actividad de CP fueron mayores en pacientes con ECC que en sujetos sanos; (417±295 vs. 179±145 ng/mL, p=0,0018); (891±179 vs. 630±115 IU/L, p< 0,0001) respectivamente y la asociación entre las variables fue estadísticamente significativa (r=0,47, p=0,0272). La liberación sistémica de MPO que conduce a valores incrementados de su concentración sérica, y la hiperceruloplasminemia podrían considerarse un rasgo característico de ECC asintomática e indicarían aterosclerosis en pacientes que eventualmente desarrollen ECC.


Subject(s)
Humans , Ceruloplasmin , Peroxidase , Atherosclerosis , Inflammation
19.
Acta bioquím. clín. latinoam ; 47(1): 53-59, mar.2013. graf
Article in Spanish | BINACIS | ID: bin-129802

ABSTRACT

La ceruloplasmina (CP) es una proteína que participa en el metabolismo del hierro y transporta el 95% del cobre plasmático. Se considera un inhibidor fisiológico de la mieloperoxidasa (MPO), enzima leucocitaria que forma parte del sistema inmune innato. Ambas se postulan como biomarcadores de la enfermedad cardiovascular. El objetivo del presente trabajo fue determinar la actividad de CP y la concentración de MPO en pacientes con enfermedad coronaria crónica (ECC) y analizar su asociación con otros parámetros de inflamación. Se estudiaron 22 pacientes con ECC y 22 controles sanos. La actividad de CP fue determinada por el método de Ozcan Erel y las concentraciones de MPO, proteína C- reactiva ultrasensible (PCR-us) e Interleuquina 6 (IL-6) por métodos estandarizados. La concentración de MPO y la actividad de CP fueron mayores en pacientes con ECC que en sujetos sanos; (417±295 vs. 179±145 ng/mL, p=0,0018); (891±179 vs. 630±115 IU/L, p< 0,0001) respectivamente y la asociación entre las variables fue estadísticamente significativa (r=0,47, p=0,0272). La liberación sistémica de MPO que conduce a valores incrementados de su concentración sérica, y la hiperceruloplasminemia podrían considerarse un rasgo característico de ECC asintomática e indicarían aterosclerosis en pacientes que eventualmente desarrollen ECC.(AU)


Subject(s)
Humans , Ceruloplasmin , Peroxidase , Inflammation , Atherosclerosis
20.
Invest. clín ; 52(4): 365-375, dic. 2011. ilus
Article in English | LILACS | ID: lil-659226

ABSTRACT

A patient with localized cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis infection was treated with an antigen containing heat-killed L. (L.) amazonensis promastigotes plus BCG. Expression of T-cell differentiation, memory and senescence receptors markers were analyzed on T cell subpopulations, in order to establish the correlation between the percentages of expression of these receptors and his clinical status, at different stages of his follow up. The following case reports on the achievement of a successful clinical outcome with complete resolution after receiving immunotherapy. A thorough clinical and immunological follow up supporting the healing process of this patient’s lesion is presented in detail.


Un paciente con leishmaniasis cutánea localizada producida por Leishmania (Leishmania) amazonensis fue tratado con un antígeno compuesto por promastigotes de L. (L.) amazonensis muertos por calor combinado con BCG. Se analizó la expresión de distintos receptores de diferenciación, de memoria y de senescencia en las subpoblaciones de células T, con el fin de establecer una relación entre los porcentajes de expresión de dichos receptores y la clínica del paciente en diferentes momentos del seguimiento. Se reporta en este caso un resultado exitoso, con resolución completa de la lesión después de recibir la inmunoterapia, y se presenta en detalle un seguimiento clínico e inmunológico completo durante el proceso de curación.


Subject(s)
Adult , Humans , Male , Antigens, Protozoan/therapeutic use , BCG Vaccine/therapeutic use , Immunotherapy, Active , Leishmania mexicana/immunology , Leishmaniasis, Cutaneous/therapy , Occupational Diseases/therapy , Protozoan Vaccines/therapeutic use , Antigens, Protozoan/administration & dosage , Antigens, Protozoan/immunology , Argentina/epidemiology , BCG Vaccine/administration & dosage , Fisheries , Immunity, Cellular , Immunologic Memory , Injections, Intradermal , Leg Ulcer/etiology , Leg Ulcer/parasitology , Leishmania mexicana/growth & development , Leishmaniasis, Cutaneous/epidemiology , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/parasitology , Occupational Diseases/immunology , Occupational Diseases/parasitology , Protozoan Vaccines/administration & dosage , Protozoan Vaccines/immunology , T-Lymphocyte Subsets/immunology , Vaccines, Inactivated
SELECTION OF CITATIONS
SEARCH DETAIL
...